Cargando…
Biosimilar insulins: a European perspective
Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimila...
Autores principales: | DeVries, J H, Gough, S C L, Kiljanski, J, Heinemann, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403967/ https://www.ncbi.nlm.nih.gov/pubmed/25376600 http://dx.doi.org/10.1111/dom.12410 |
Ejemplares similares
-
Introduction of biosimilar insulins in Europe
por: Davies, M., et al.
Publicado: (2017) -
Biosimilar insulins: guidance for data interpretation by clinicians and users
por: Heinemann, L., et al.
Publicado: (2015) -
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015) -
The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021) -
The Future of Biosimilar Insulins
por: Kim, Anne Park, et al.
Publicado: (2016)